Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96EY8

UPID:
MMAB_HUMAN

ALTERNATIVE NAMES:
ATP:co(I)rrinoid adenosyltransferase MMAB; Methylmalonic aciduria type B protein

ALTERNATIVE UPACC:
Q96EY8; C5HU05; Q9BSH0

BACKGROUND:
The protein Corrinoid adenosyltransferase MMAB, alternatively named ATP:co(I)rrinoid adenosyltransferase and Methylmalonic aciduria type B protein, is integral to the conversion of vitamin B12 into its active form. It specifically catalyzes the transformation of cob(I)alamin to adenosylcobalamin, thereby facilitating the proper function of methylmalonyl-CoA mutase. This action is crucial for the metabolism of certain lipids and amino acids.

THERAPEUTIC SIGNIFICANCE:
Corrinoid adenosyltransferase MMAB's malfunction is associated with Methylmalonic aciduria type cblB, a disorder stemming from defective adenosylcobalamin synthesis. The exploration of MMAB's role could lead to innovative therapeutic approaches aimed at correcting the genetic abnormalities responsible for this metabolic disease.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.